<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02578810</url>
  </required_header>
  <id_info>
    <org_study_id>MUGraz2</org_study_id>
    <nct_id>NCT02578810</nct_id>
  </id_info>
  <brief_title>PIERS and BIS, sFIT:PIGF, Adrenomedullin</brief_title>
  <acronym>BIS2</acronym>
  <official_title>Sensitivity and Specificity of Bispectral Index (BIS) EEG Parameter, sFIT (Soluble FMS Tyrosine Kinase): PIGF (Placental Growth Factor) Ratio, Adrenomedullin for Grading Preeclampsia Integrated Estimate Risk Score (PIERS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suez Canal University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Suez Canal University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pre-eclampsia, more than being proteinuric gestational hypertension alone, is a state of&#xD;
      exaggerated systemic inflammation and remains a leading direct cause of maternal morbidity&#xD;
      and mortality worldwide.1 Standardization of antenatal and postnatal assessment and&#xD;
      surveillance of pre-eclampsia with protocols that recognize the systemic inflammatory model&#xD;
      of preeclampsia have been associated with reduced maternal morbidity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Pre-eclampsia, more than being proteinuric gestational hypertension alone, is a&#xD;
      state of exaggerated systemic inflammation and remains a leading direct cause of maternal&#xD;
      morbidity and mortality worldwide.1 Standardization of antenatal and postnatal assessment and&#xD;
      surveillance of pre-eclampsia with protocols that recognize the systemic inflammatory model&#xD;
      of preeclampsia have been associated with reduced maternal morbidity.2 To quantitatively&#xD;
      asses electroencephalography (EEG) mental involvement in Pre-eclampsia is still time&#xD;
      consuming and not always readily available. PIERS was developed and internally validate as a&#xD;
      pre-eclampsia outcome prediction model- (Preeclampsia Integrated Estimate of RiSk) model.3&#xD;
      The purpose of our study was to evaluate the discriminative power of the Bispectral Index&#xD;
      (BIS), biomarkers sFIT (soluble FMS-like Tyrosine Kinase): PIGF (Placental Growth Factor)&#xD;
      ratio,4 and adrenomedullin mortality risk stratifier,5 to classify the degree and progression&#xD;
      of pre-eclampsia.&#xD;
&#xD;
      Methods: In 24 patients with Eclampsia or pre-eclampsia investigators will use an&#xD;
      artefact-free 20-min mean BIS value, as well as biomarkers sFIT (soluble FMS-like Tyrosine&#xD;
      Kinase): PIGF (Placental Growth Factor) ratio and adrenomedullin mortality risk stratifier to&#xD;
      classify the degree of pre-eclampsia correlated the PIERS Pre-eclampsia risk assessment PIERS&#xD;
      percentage (http://piers.cfri.ca/PIERSCalculatorH.aspx) will be calculated from patients'&#xD;
      clinical and laboratory findings documented in their charts, compared with 24 pregnant&#xD;
      patients without Eclampsia or pre-eclampsia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Decline in BIS</measure>
    <time_frame>we will record Bispectral Index (BIS) for a quite 20 min no tactile contact or noise that could raise the BIS inadvertently</time_frame>
    <description>our hypothesis is that a decline of Bispectral Index (BIS) assuming to be in the range of 15-60 will correlate to the with a high PIERS we can then quantify this BIS decline maybe in 4 Eclampsia grades</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Eclampsia</condition>
  <arm_group>
    <arm_group_label>Eclampsia</arm_group_label>
    <description>In 24 patients with Eclampsia or pre-eclampsia investigators will use an artefact-free 20-min mean BIS value, as well as biomarkers sFIT (soluble FMS-like Tyrosine Kinase): PIGF (Placental Growth Factor) ratio and adrenomedullin mortality risk stratifier to classify the degree of pre-eclampsia correlated the PIERS Pre-eclampsia risk assessment PIERS percentage (http://piers.cfri.ca/PIERSCalculatorH.aspx) will be calculated from patients' clinical and laboratory findings documented in their charts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>In 24 control patients without Eclampsia or pre-eclampsia investigators will use an artefact-free 20-min mean BIS value, as well as biomarkers sFIT (soluble FMS-like Tyrosine Kinase): PIGF (Placental Growth Factor) ratio and adrenomedullin mortality risk stratifier to classify the degree of pre-eclampsia correlated the PIERS Pre-eclampsia risk assessment PIERS percentage (http://piers.cfri.ca/PIERSCalculatorH.aspx) will be calculated from patients' clinical and laboratory findings documented in their charts</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        24 patients with Eclampsia or pre-eclampsia investigators will use an artefact-free 20-min&#xD;
        mean BIS value, as well as biomarkers sFIT (soluble FMS-like Tyrosine Kinase): PIGF&#xD;
        (Placental Growth Factor) ratio and adrenomedullin mortality risk stratifier to classify&#xD;
        the degree of pre-eclampsia correlated the PIERS Pre-eclampsia risk assessment PIERS&#xD;
        percentage (http://piers.cfri.ca/PIERSCalculatorH.aspx) will be calculated from patients'&#xD;
        clinical and laboratory findings documented in their charts, compared with 24 pregnant&#xD;
        patients without Eclampsia or pre-eclampsia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Pregnancy at any stage (3 trimesters)&#xD;
&#xD;
          2. Eclampsia (Frank eclampsia) will be the crux of the study&#xD;
&#xD;
          3. Pre-eclampsia that is suspected will end up with Frank Eclampsia&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Any neurological conditions that can alter the electroencephalography like epilepsy&#xD;
&#xD;
          2. Any medical conditions that can alter the electroencephalography like hypoglycemia&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashraf Dahaba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guest Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashraf Dahaba, MD</last_name>
    <phone>00436509006761</phone>
    <email>ashraf.dahaba@medunigraz.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Ethics Committee, University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashraf Dahaba</last_name>
      <email>ashraf.dahaba@medunigraz.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2015</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Suez Canal University</investigator_affiliation>
    <investigator_full_name>Ashraf A. Dahaba</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eclampsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

